A share price of Vistagen Therapeutics Inc [VTGN] is currently trading at $0.74, down -14.05%. An important factor to consider is whether the stock is rising or falling in short-term value. The VTGN shares have lost -81.27% over the last week, with a monthly amount drifted -84.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vistagen Therapeutics Inc [NASDAQ: VTGN] stock has seen the most recent analyst activity on December 17, 2025, when William Blair downgraded its rating to a Mkt Perform. Previously, Stifel downgraded its rating to Hold on December 17, 2025, and kept the price target unchanged to $1. On December 17, 2025, downgrade downgraded it’s rating to Hold. Jefferies downgraded its rating to a Hold but stick to its price target of $0.90 on December 17, 2025. Jefferies upgraded its rating to a Buy but $15 remained the price target by the analyst firm on December 07, 2023. Maxim Group upgraded its rating to Buy for this stock on August 07, 2023, but kept the price target unchanged to $30. In a note dated July 22, 2022, William Blair downgraded an Mkt Perform rating on this stock.
Vistagen Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.75 and $5.14. Currently, Wall Street analysts expect the stock to reach $0.95 within the next 12 months. Vistagen Therapeutics Inc [NASDAQ: VTGN] shares were valued at $0.74 at the most recent close of the market. An investor can expect a potential return of 28.38% based on the average VTGN price forecast.
Analyzing the VTGN fundamentals
Trailing Twelve Months sales for Vistagen Therapeutics Inc [NASDAQ:VTGN] were 0.70M which represents 207.14% growth. Gross Profit Margin for this corporation currently stands at 0.41% with Operating Profit Margin at -90.81%, Pretax Profit Margin comes in at -86.32%, and Net Profit Margin reading is -86.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.77, Equity is -0.91 and Total Capital is -0.97. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6993 points at the first support level, and at 0.6586 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8115, and for the 2nd resistance point, it is at 0.8830.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vistagen Therapeutics Inc [NASDAQ:VTGN] is 5.79. On the other hand, the Quick Ratio is 5.79, and the Cash Ratio is 4.6. Considering the valuation of this stock, the price to sales ratio is 41.76, the price to book ratio is 0.43.
